title: Oncolytic virotherapy needs trials, not access programs.
abstract: Oncolytic virotherapy is a novel treatment for cancer that exerts direct lytic and indirect immune-mediated antitumor effects. A Finnish research team has reported on an advanced therapy access program for oncolytic adenovirus. The strengths and weaknesses of this approach are highlighted with a view to informing future study conduct.
authors.affiliation: The Institute of Cancer Research, Targeted Therapy Team, London, United Kingdom. Kevin.Harrington@icr.ac.uk
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Harrington
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D013601:T-Lymphocytes / Q000276:immunology*